alexa Novel Approach For Treating Complicated Intra-abdominal Infection (cIAI) And Sepsis
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th International Congress on Bacteriology and Infectious Diseases
May 25-26, 2017 Chicago, USA

Suchismita Acharya, Pragnya Das, Beamon Agarwal and Santosh K Panda
AyuVis Research LLC, USA
ScientificTracks Abstracts: J Bacteriol Parasitol
DOI: 10.4172/2155-9597-C1-028
Intra-abdominal infection (IAI) is an important cause of morbidity and mortality. It is the second most commonly identified cause of severe sepsis in the intensive care unit (ICU). Recent studies have associated severe intra-abdominal infection with a significant mortality rate. Most IAI are a result of processes involving inflammation and perforations of the gastrointestinal tract, such as appendicitis, peptic ulcer disease, and diverticulitis. Patients with diffuse peritonitis may be due to spontaneous perforation, post-operative, post-interventional or post-traumatic causes. The lower GI tract is most often the location of perforation. Among patients with IAI who develop peritonitis, many may progress to severe sepsis, defined by The American College of Chest Physicians/ Society of Critical Care Medicine as a severe systemic inflammatory response to infection that is associated with acute organ dysfunction. AyuVis Research’s overarching goal is to develop and commercialize a small molecular weight, water soluble, compound useful in adjunctive and/or in combination therapy via intravenous (IV) dosing for complicated intra- abdominal infection that may lead to sepsis. We have reported a novel approach to treat secondary or tertiary peritonitis leading to sepsis and death fundamentally different from other reports. This multi-functional small molecule AyuV-25 by virtue of its ability to bind to the active sites of TLR4 can competitively inhibit LPS induced inflammation as well as produce alternately activated macrophages leading to organ protection and tissue repair. Preliminary results from AyuVis demonstrated that compound AyuV-25 protected mice (12 weeks old) against lethal polymicrobial infection in cecal ligation and puncture (CLP) model alone, and in combination with standard antibiotic primaxin via intravenous (IV) dosing. In this presentation, we will discuss some of the preclinical results in animal model.

Dr. Suchi Acharya has more than 15 years of pharmaceutical drug discovery, development, pre-clinical, clinical and regulatory affairs experiences from Novartis and Alcon Research. She is the founder and CEO of AyuVis Research. She is also the lead inventor of the underlying this small molecule technology and the PI of the SBIR grant sponsored by NIAID/NIH. She is an experienced investigator and also holds Research Assistant Professor position in UNT Health Science Center, Fort Worth, Texas.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version